483-P: Pioglitazone Suppresses Macrophage Proliferation in Apolipoprotein-e Deficient Mice by Activating PPARγ

• Published in: Diabetes (New York, N.Y.) Vol. 68; no. Supplement_1
• Main Authors: MURAKAMI-NISHIDA, SAIKO, MATSUMURA, TAKESHI, NISHIDA, SHUHEI, SENOKUCHI, TAKAFUMI, ISHII, NORIO, YAMADA, SARIE, MORITA, YUTARO, WADA, TOSHIAKI, MOTOSHIMA, HIROYUKI, KONDO, TATSUYA, ARAKI, EIICHI
• Format: Journal Article
• Language: English
• Published: 01.06.2019
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db19-483-P

Background and Aims: Local macrophage proliferation in the atherosclerotic plaque is linked to the enhanced atherosclerosis progression. Although we reported that troglitazone, a thiazolidinedione (TZD), suppressed oxidized low-density lipoprotein (Ox-LDL)-induced macrophage proliferation, its mechanisms have been unclear. We therefore investigated the mechanism(s) of the inhibitory effect of macrophage proliferation by another TZD, pioglitazone. Methods: High-fat diet (HFD)-fed, apolipoprotein E-deficient (ApoE KO) mice were treated orally with pioglitazone (10 mg/kg/day). After 8 weeks of treatment, the whole aorta or frozen sections of the aortic sinus were stained with Oil red O. To identify macrophage proliferation and apoptosis, we performed Ki67/Iba-1 double immunohistochemical staining and TUNEL method, respectively. Results: Atherosclerosis progression was suppressed in aortic sinuses of pioglitazone-treated ApoE KO mice, and they showed fewer proliferating macrophages in the plaques. Pioglitazone suppressed Ox-LDL-induced macrophage proliferation in a dose-dependent manner, which was ameliorated by peroxisome proliferator-activated receptor-γ (PPARγ) siRNA. Low concentrations (less than 100 µM) of pioglitazone, which can suppress macrophage proliferation, activated PPARγ in macrophages, but did not induce macrophage apoptosis. Pioglitazone did not induce TUNEL-positive cells in atherosclerotic plaques in ApoE KO mice. Conclusions: Pioglitazone suppresses macrophage proliferation through PPARγ without inducing macrophage apoptosis. These findings imply that pioglitazone could prevent macrovascular complications in diabetics. Disclosure S. Murakami-Nishida: None. T. Matsumura: None. S. Nishida: None. T. Senokuchi: None. N. Ishii: None. S. Yamada: None. Y. Morita: None. T. Wada: None. H. Motoshima: None. T. Kondo: None. E. Araki: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Novo Nordisk Inc., Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Astellas Pharma Inc., Merck & Co., Inc., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi.